Glycemic variability is associated with sural nerve conduction velocity in outpatients with type 2 diabetes: Usefulness of a new point‐of‐care device for nerve conduction studies

Abstract

ABSTRACTAims/IntroductionAlthough several studies have shown the association between continuous glucose monitoring (CGM)‐derived glycemic variability (GV) and diabetic peripheral neuropathy, no studies have focused on outpatients or used NC‐stat®/DPNCheck™, a new point‐of‐care device for nerve conduction study (NCS). We investigated the association between CGM‐derived GV and NCS using DPNCheck™ in outpatients with type 2 diabetes, and further analyzed the difference in results between patients with and without well‐controlled HbA1c levels.Materials and MethodsAll outpatients with type 2 diabetes using the CGM device (FreeStyle Libre Pro®) between 2017 and 2022 were investigated. Sural nerve conduction was evaluated by sensory nerve action potential (SNAP) amplitude and sensory conduction velocity (SCV) using DPNCheck™. Associations of CGM‐derived GV metrics with SNAP amplitude and SCV were investigated.ResultsIn total, 304 outpatients with type 2 diabetes were included. In a linear regression model, most CGM‐derived GV metrics except for the mean amplitude of glucose excursion and low blood glucose index were significantly associated with SCV, but not with SNAP amplitude. The significant associations of most CGM‐derived GV metrics with SCV remained after adjustment for possible confounding factors, but not after adjustment for glycated hemoglobin (HbA1c). Most CGM‐derived GV metrics were significantly associated with SCV after adjustment for HbA1c in patients with a HbA1c ≤ 6.9%, but not in those with a HbA1c ≥ 7.0%.ConclusionsIn outpatients with type 2 diabetes, multiple CGM‐derived GV metrics were significantly associated with SCV obtained by DPNCheck™. GV may have independent impacts on peripheral nerve function, particularly in patients with well‐controlled HbA1c levels.